The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II preoperative pembrolizumab for MSI high or MSS/PD-L1 gastric cancer followed by surgery and adjuvant therapy with pembrolizumab (NCT03257163): Results of a multicenter study.
 
Timothy Kennedy
No Relationships to Disclose
 
Mihir Shah
No Relationships to Disclose
 
Rafi Kabarriti
Research Funding - Varian Medical Systems (Inst)
 
Patrick Boland
Consulting or Advisory Role - BeiGene; Bristol Myers Squibb Foundation; Taiho Oncology
Research Funding - Caris Life Sciences (Inst); Compass Therapeutics (Inst); MEI Pharma (Inst); Merck (Inst); Processa Pharmaceuticals (Inst)
 
Haejin In
No Relationships to Disclose
 
Chunxia Chen
No Relationships to Disclose
 
Stephen Szabo
No Relationships to Disclose
 
Howard Hochster
No Relationships to Disclose
 
Dirk Moore
No Relationships to Disclose
 
Salma Jabbour
Honoraria - Advarra; IMX Medical Reviewer; Merck; Novocure; Radialogica; syntactx
Consulting or Advisory Role - AstraZeneca; AstraZeneca; BeiGene; IMX Medical Reviewer; Merck Sharp & Dohme; Syntactx
Research Funding - Beigene (Inst); Merck Sharp & Dohme (Inst); Natera (Inst); NCI (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck